195 The Impact of Administration of Leukotriene Receptor Antagonists, Pranlukast-EK to Infants with Bronchial Asthma
نویسندگان
چکیده
increased the time to first asthma deterioration thus decreasing the proportion of subjects experiencing asthma deterioration during the study (MF/F 1⁄4 16.5%; versus MF 1⁄4 28.2% [P 1⁄4 0.006]; versus F 1⁄4 44.7% [P , 0.001]; and vs placebo 1⁄4 45.7% [P , 0.001]). Mean FEV1 AUC0–12h over baseline at week 12 were MF/F 1⁄4 4.00 L · h; MF 1⁄4 2.53 L · h; F 1⁄4 3.83 L · h; and placebo 1⁄4 1.11 L · h. Low rates of AEs were observed and were similar between treatment arms. Conclusions: In asthmatics previously treated with low-dose ICS with or without a LABA, MF/F 100/10 mg BID was more effective than placebo, MF, or F (all administered by MDI) in reducing asthma deteriorations and improving lung function.
منابع مشابه
Leukotriene receptor antagonists pranlukast and montelukast for treating asthma
Introduction The prevalence of bronchial asthma, which is a chronic inflammatory disorder of the airway, is increasing worldwide. Although inhaled corticosteroids (ICS) play a central role in the treatment of asthma, they cannot achieve good control for all asthmatics and medications such as leukotriene receptor antagonists (LTRAs) with bronchodilatory and anti-inflammatory effects often serve ...
متن کاملLeukotriene receptor antagonists pranlukast and montelukast for treating asthma.
INTRODUCTION The prevalence of bronchial asthma, which is a chronic inflammatory disorder of the airway, is increasing worldwide. Although inhaled corticosteroids (ICS) play a central role in the treatment of asthma, they cannot achieve good control for all asthmatics, and medications such as leukotriene receptor antagonists (LTRAs) with bronchodilatory and anti-inflammatory effects often serve...
متن کاملEffect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers.
BACKGROUND There is increasing evidence to show that leukotrienes are important mediators in asthma. Leukotriene receptor antagonists protect against antigen and exercise challenges in patients with chronic asthma. A study was undertaken to investigate the activity of the leukotriene receptor antagonist pranlukast (SB 205312, ONO-1078) in blocking bronchoconstriction induced by leukotriene D4 (...
متن کاملPranlukast, a cysteinyl leukotriene antagonist, reduces serum eosinophil cationic protein levels in patients with asthma.
Cysteinyl leukotrienes (cysLTs) are considered to be important mediators involved in bronchial asthma and the ensuing eosinophilic inflammation. We evaluated the effects of pranlukast, a potent and selective cysLT receptor antagonist, on the clinical course and serum eosinophil cationic protein (ECP) levels of 10 asthmatic patients. A four-week administration of pranlukast increased the morning...
متن کاملComparative evaluation of the leukotriene receptor antagonist pranlukast versus the steroid inhalant fluticasone in the therapy of aged patients with mild bronchial asthma.
A comparative study was conducted in elderly subjects with mild bronchial asthma to investigate the clinical usefulness of monotherapy with a leukotriene receptor antagonist in comparison to an inhaled corticosteroid. A total of 41 elderly patients aged 65 years or older with mild bronchial asthma, classified as being in severity step 1 and 2, were randomly assigned to the following two treatme...
متن کامل